Okyo Names Robert Dempsey CEO: Leadership Update

by

Here’s⁢ a breakdown of the provided text, focusing on key facts and structure:

Overall summary:

This article announces the appointment of Robert J. Dempsey as the new CEO of Okyo Pharma. The move is intended to support the company’s advancement of urcosimod, a drug in advancement for neuropathic corneal pain and ocular inflammatory disorders. The previous CEO, Gary S. Jacob, will transition to the role of Chief⁢ Development ⁣Officer.

Key Information:

* New CEO: Robert J. dempsey
* Company: Okyo ⁣Pharma
* Previous CEO: ⁤ Gary S. Jacob (now Chief Development Officer)
* ‍ Drug in Development: urcosimod (formerly OK-101)
* conditions Targeted: Neuropathic corneal pain and ocular inflammatory disorders.
* FDA Status: Urcosimod has received Fast Track designation from the FDA (May 2025).
* Clinical Trial Results: Phase 2 trial showed pain reduction in patients with neuropathic corneal pain.
* Dempsey’s Experience: Over 20 years in global ophthalmology, including leading the launch of Xiidra at‍ Shire.
* Future Focus: Phase 2b study execution‍ and establishing Okyo as a leader in⁣ neuropathic corneal pain treatment.

Article Structure:

  1. Introductory⁣ Paragraphs: Announce the CEO appointment and highlight Dempsey’s experience.
  2. Drug Information: Details about⁢ urcosimod, its development stage,‍ and clinical trial results.
  3. CEO Transition: Explains Gary S. Jacob’s new role.
  4. Quote from Dempsey: Provides‍ insight into his ⁢vision⁢ for the company and the‍ potential impact of urcosimod.
  5. Source/Disclosure: Identifies the source of the information (a press release) and any relevant‍ disclosures (Dempsey’s employment ⁣by‍ Okyo⁣ Pharma).
  6. Healio AI Promotion: An advertisement for Healio’s AI tool.
  7. Footer: Publisher logo.

additional Notes:

* The article includes a figure (image) with a caption ⁣summarizing Dempsey’s experience.
* There are links to related articles on Healio regarding urcosimod’s FDA designation and phase 2 trial‍ results.
* The HTML includes some code related to a modal window for‍ error messages (likely a technical ⁤element for the website).

Related reading

Leave a Comment